Literature DB >> 22869300

Chondrogenic differentiation of amniotic fluid stem cells and their potential for regenerative therapy.

Andrea Preitschopf1, Hannes Zwickl, Kongzhao Li, Gert Lubec, Gabor Joo, Margit Rosner, Markus Hengstschläger, Mario Mikula.   

Abstract

Chronic articular cartilage defects are the most common disabling conditions of humans in the western world. The incidence for cartilage defects is increasing with age and the most prominent risk factors are overweight and sports associated overloading. Damage of articular cartilage frequently leads to osteoarthritis due to the aneural and avascular nature of articular cartilage, which impairs regeneration and repair. Hence, patients affected by cartilage defects will benefit from a cell-based transplantation strategy. Autologous chondrocytes, mesenchymal stem cells and embryonic stem cells are suitable donor cells for regeneration approaches and most recently the discovery of amniotic fluid stem cells has opened a plethora of new therapeutic options. It is the aim of this review to summarize recent advances in the use of amniotic fluid stem cells as novel cell sources for the treatment of articular cartilage defects. Molecular aspects of articular cartilage formation as well as degeneration are summarized and the role of growth factor triggered signaling pathways, scaffolds, hypoxia and autophagy during the process of chondrogenic differentiation are discussed.

Entities:  

Mesh:

Year:  2012        PMID: 22869300     DOI: 10.1007/s12015-012-9405-4

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  89 in total

Review 1.  Potential of human embryonic stem cells in cartilage tissue engineering and regenerative medicine.

Authors:  Wei Seong Toh; Eng Hin Lee; Tong Cao
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

2.  The combination of SOX5, SOX6, and SOX9 (the SOX trio) provides signals sufficient for induction of permanent cartilage.

Authors:  Toshiyuki Ikeda; Satoru Kamekura; Akihiko Mabuchi; Ikuyo Kou; Shoji Seki; Tsuyoshi Takato; Kozo Nakamura; Hiroshi Kawaguchi; Shiro Ikegawa; Ung-il Chung
Journal:  Arthritis Rheum       Date:  2004-11

Review 3.  Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Nat Clin Pract Rheumatol       Date:  2008-03

4.  The dependence of autologous chondrocyte transplantation on varying cellular passage, yield and culture duration.

Authors:  Gian M Salzmann; Martin Sauerschnig; Markus T Berninger; Theresa Kaltenhauser; Martin Schönfelder; Stephan Vogt; Gabriele Wexel; Thomas Tischer; Norbert Sudkamp; Philipp Niemeyer; Andreas B Imhoff; Philip B Schöttle
Journal:  Biomaterials       Date:  2011-05-17       Impact factor: 12.479

5.  Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source.

Authors:  Yusuke Sakaguchi; Ichiro Sekiya; Kazuyoshi Yagishita; Takeshi Muneta
Journal:  Arthritis Rheum       Date:  2005-08

6.  Runx3/AML2/Cbfa3 regulates early and late chondrocyte differentiation.

Authors:  Do Y Soung; Yufeng Dong; YongJun Wang; Michael J Zuscik; Edward M Schwarz; Regis J O'Keefe; Hicham Drissi
Journal:  J Bone Miner Res       Date:  2007-08       Impact factor: 6.741

7.  Transcriptional activation of cartilage oligomeric matrix protein by Sox9, Sox5, and Sox6 transcription factors and CBP/p300 coactivators.

Authors:  Chuan-ju Liu; Yan Zhang; Ke Xu; Deidre Parsons; Daniel Alfonso; Paul E Di Cesare
Journal:  Front Biosci       Date:  2007-05-01

8.  S100A1 and S100B, transcriptional targets of SOX trio, inhibit terminal differentiation of chondrocytes.

Authors:  Taku Saito; Toshiyuki Ikeda; Kozo Nakamura; Ung-il Chung; Hiroshi Kawaguchi
Journal:  EMBO Rep       Date:  2007-03-30       Impact factor: 8.807

9.  Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2.

Authors:  Alfredo Toschi; Evan Lee; Noga Gadir; Michael Ohh; David A Foster
Journal:  J Biol Chem       Date:  2008-10-22       Impact factor: 5.157

10.  Mechanisms of GDF-5 action during skeletal development.

Authors:  P H Francis-West; A Abdelfattah; P Chen; C Allen; J Parish; R Ladher; S Allen; S MacPherson; F P Luyten; C W Archer
Journal:  Development       Date:  1999-03       Impact factor: 6.868

View more
  5 in total

Review 1.  Challenges in engineering osteochondral tissue grafts with hierarchical structures.

Authors:  Ivana Gadjanski; Gordana Vunjak-Novakovic
Journal:  Expert Opin Biol Ther       Date:  2015-07-20       Impact factor: 4.388

2.  Comparative analysis of multilineage properties of mesenchymal stromal cells derived from fetal sources shows an advantage of mesenchymal stromal cells isolated from cord blood in chondrogenic differentiation potential.

Authors:  Alice Pievani; Valeria Scagliotti; Francesca Maria Russo; Isabella Azario; Benedetta Rambaldi; Benedetto Sacchetti; Simona Marzorati; Eugenio Erba; Giovanni Giudici; Mara Riminucci; Andrea Biondi; Patrizia Vergani; Marta Serafini
Journal:  Cytotherapy       Date:  2014-05-01       Impact factor: 5.414

3.  Comparison of Four Protocols to Generate Chondrocyte-Like Cells from Human Induced Pluripotent Stem Cells (hiPSCs).

Authors:  Wiktoria Maria Suchorska; Ewelina Augustyniak; Magdalena Richter; Tomasz Trzeciak
Journal:  Stem Cell Rev Rep       Date:  2017-04       Impact factor: 5.739

4.  Rapamycin-Induced Hypoxia Inducible Factor 2A Is Essential for Chondrogenic Differentiation of Amniotic Fluid Stem Cells.

Authors:  Andrea Preitschopf; David Schörghofer; Katharina Kinslechner; Birgit Schütz; Hannes Zwickl; Margit Rosner; József Gabor Joó; Stefan Nehrer; Markus Hengstschläger; Mario Mikula
Journal:  Stem Cells Transl Med       Date:  2016-03-29       Impact factor: 6.940

Review 5.  Fetal stem cells and skeletal muscle regeneration: a therapeutic approach.

Authors:  Michela Pozzobon; Chiara Franzin; Martina Piccoli; Paolo De Coppi
Journal:  Front Aging Neurosci       Date:  2014-08-27       Impact factor: 5.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.